Latest news with #PatrikJonsson
Yahoo
08-05-2025
- Business
- Yahoo
Eli Lilly (NYSE:LLY) Announces Executive Changes To Drive Global Growth And Pipeline Advancement
Eli Lilly recently announced leadership transitions, including new roles for Ilya Yuffa, Patrik Jonsson, and Kenneth Custer, marking a strategic shift aiming to expand its global market presence and enhance product reach. Over the past month, the company's stock appreciated by 7%, potentially reflecting investor confidence in its direction amid these changes. Strong quarterly financial results, with significant increases in sales and earnings, would have bolstered investor sentiment. While broader market trends showed an upward trajectory with the Dow Jones and S&P 500 also rising, Eli Lilly's comprehensive developments likely added weight to its favorable performance. We've identified 2 possible red flags with Eli Lilly (at least 1 which is a bit concerning) and understanding the impact should be part of your investment process. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Eli Lilly's recent leadership transitions could bolster its strategic focus on global market expansion, potentially impacting its revenue and earnings forecasts. The company aims to enhance its product reach, particularly in oncology and immunology, areas of anticipated growth based on the release of Phase III trial data. These developments are positioned against the backdrop of significant investments in manufacturing and R&D, which could optimize production efficiency and improve supply chain resilience, key factors for revenue growth despite potential short-term costs. Looking at its longer-term performance, Eli Lilly's stock appreciated by 422.93% over the past five years, reflecting substantial growth compared to the US Pharmaceuticals industry. Over the past year, while the industry experienced a shrinkage of 7.3%, Eli Lilly managed to outperform this trend with notable performance this must be viewed in the context of a broader market comparison over the same period where the US market saw a return of 7.7%, meaning Eli Lilly's performance was not as strong in that specific timeframe. The recent 7% share price increase, amid expectations of revenue reaching US$85.1 billion and earnings climbing to US$31.7 billion by 2028, indicates investor positivity. Analysts' consensus price target of US$981.63 suggests a 21% potential increase from the current share price of US$775.12, though it's essential for investors to analyze these figures alongside potential risks such as pricing pressures and regulatory challenges. Prudence is advised when considering the alignment of actual future outcomes with these optimistic forecasts. Click here to discover the nuances of Eli Lilly with our detailed analytical financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:LLY. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17-04-2025
- Business
- Yahoo
Weight loss in a pill? Eli Lilly just took a big step closer to making it happen.
Drugmaker Eli Lilly announced promising Phase 3 study results for its new GLP-1 pill. Orforglipron is a drug similar to Ozempic but without the injection, making it more accessible. The pill, poised to revolutionize the weight loss world, may be up for FDA approval in late 2025. A daily pill to rival Ozempic is one step closer to hitting the market. Pharmaceutical giant Eli Lilly saw its stock jump Thursday morning after announcing initial Phase 3 trial results on orforglipron, a highly anticipated medication for diabetes and weight loss. The drug is in the same class of GLP-1 medications as Ozempic, Wegovy, Mounjaro, and Zepbound — weekly injections that upended the weight-loss industry — but in pill form. Lilly's head of diabetes and obesity Patrik Jonsson recently told Business Insider that orforglipron will likely unlock a much wider market, bringing the benefits of groundbreaking weight-loss drugs to people who can't, or don't want to, use injections. "Most importantly, when you look at the global need, we expect that there are more than one billion people across the globe that are suffering from obesity," Jonsson said. "There is no way that we can meet those demands with injectable treatments today." Lilly is racing to bring the first pill version of a GLP-1 for weight loss to market against competitors like Novo Nordisk and Pfizer, whose prospects have not lived up to expectations. Novo Nordisk's Rybelsus, a daily pill with the same properties as Ozempic, was FDA-approved for diabetes in 2019. However, its weight loss results didn't stack up to other GLP-1 drugs in studies, and it's not straightforward to take; users need to fast before and for 30 minutes after taking the pill. Pfizer's daily pill, danuglipron, was scrapped after one study participant developed liver problems and recovered after they stopped taking the drug. If all goes well for Lilly, orforglipron could be up for FDA approval for weight management by the end of 2025, and for type 2 diabetes treatment in 2026. In the topline results released today, adults with diabetes who took orforglipron for 40 weeks had significantly better blood sugar control than those who took a placebo, according to a press release from Lilly. They also lost up to 16 pounds (about 7.6% of their body weight) on average while taking the highest dose, and hadn't plateaued by the end of the study, suggesting even more weight loss could be possible. The study — one of seven trials planned — found orforglipron is just as safe as other GLP-1 drugs, with the similar side effects like diarrhea and nausea. The company intends to release more data later this year, Lilly's CEO David A. Ricks said in the press release. The big question is: will it be cheaper than Ozempic, Wegovy, Mounjaro, or Zepbound? While Eli Lilly has been tight-lipped about list price, analysts say there's a good chance orforglipron could cost less than the $900 monthly list price of current drugs, since a pill is easier to produce and distribute. Read the original article on Business Insider
The Independent
25-02-2025
- Business
- The Independent
Higher dose and even cheaper: New vials of popular weight-loss drug released
American pharmaceutical company Eli Lilly has started selling higher doses of its popular weight-loss drug Zepbound in vials, at a $150 discount to the cost of the injector pen versions. On Tuesday, Lilly announced patients would be able to purchase 7.5mg and 10mg vials for U$499 a month on the LillyDirect website, nearly 23 percent less than the $650 Lilly charges for auto-injectors of the drug to patients who are insured but not covered for the medicine. Patrik Jonsson, Eli Lilly's president of cardiometabolic health, said more than 10 percent of patients starting on Zepbound have been initiated on vials since their launch. Shares of the Indiana-based drugmaker rose 2 percent to $899.28 in premarket trading. The U.S. drugmaker launched vials of the two lowest doses of Zepbound, which is typically sold in auto-injector pens, to help increase availability last August. On Tuesday, it said it had also cut the prices for a month's supply of those doses by around $50 each. They now cost $349 and $499 a month through LillyDirect. Lilly is looking for ways to stimulate further demand for Zepbound this year to help ease investor agitation over signs of weakness in sales, and to better compete with Danish rival Novo Nordisk's popular Wegovy. Novo offers Wegovy on its website for $650 for a month's supply to patients not covered by insurance for the drug, but does not sell its medicine in vials. Lilly's new offer of $499 per month is still higher than the $231 to $330 compounding pharmacies typically charge for their versions of Zepbound and Wegovy in the U.S., although compounders have been told to cease selling their copies in the coming months. Shortages of the weight-loss drugs pushed patients to cheaper compounded versions, which can be sold and distributed in bulk as long as the original drug is on the U.S. Food and Drug Administration's shortage list. In the past three months, the FDA took both Zepbound and Wegovy off its shortage list, spurring lawsuits from compounding pharmacies. Telehealth firm Hims & Hers Health late on Monday warned it may not be able to sell compounded weight-loss drugs to the same extent, or at all. Shares of Hims & Hers extended premarket losses after Lilly's announcement, falling 22.3 percent to $39.87. Shares of other telehealth firms such as LifeMD slipped 10 percent, while Teladoc Health was down two percent. Lilly said patients must refill their prescriptions of the two higher dose vials within 45 days of their first fill to get the same pricing, and would otherwise have to pay as much as $699 for repeat prescriptions. Jonsson said this requirement ensures patients comply with a dosing regimen approved by the FDA.
Yahoo
25-02-2025
- Business
- Yahoo
Lilly launches higher-dose vials of weight-loss drug Zepbound for $150 less than injector pen
(Reuters) - Eli Lilly (LLY) said on Tuesday it has begun selling higher doses of its popular weight-loss drug Zepbound in vials in the U.S. at a $150 discount to the cost of the injector pen versions, as it seeks to spur further demand for the medicine. Lilly's share price rose by almost 2% in pre-market trading on Tuesday. The drugmaker said patients could purchase 7.5 milligram and 10mg vials of Zepbound for $499 a month on the LillyDirect website. That is nearly 23% less than the $650 Lilly charges for auto-injectors of the drug to patients who are insured but not covered for the medicine. The U.S. drugmaker last August launched vials of the two lowest doses of Zepbound, which is typically sold in auto-injector pens, to help increase availability. On Tuesday, it said it had also cut the prices for a month's supply of those doses by around $50 each. They now cost $349 and $499 a month through LillyDirect. Patrik Jonsson, Eli Lilly's president of cardiometabolic health, said in an interview that more than 10% of patients starting on Zepbound have been initiated on vials since their launch. Lilly is looking for ways to stimulate further demand for Zepbound this year to help ease investor agitation over signs of weakness in sales, and to better compete with Danish rival Novo Nordisk's (NVO) popular Wegovy. Novo offers Wegovy on its website for $650 for a month's supply to patients not covered by insurance for the drug, but does not sell its medicine in vials. Lilly's new offer of $499 per month is still higher than the $231 to $330 compounding pharmacies typically charge for their versions of Zepbound and Wegovy in the U.S., although compounders have been told to cease selling their copies in the coming months. Shortages of the weight-loss drugs pushed patients to cheaper compounded versions, which can be sold and distributed in bulk as long as the original drug is on the U.S. Food and Drug Administration's shortage list. In the past three months, the FDA took both Zepbound and Wegovy off its shortage list, spurring lawsuits from compounding pharmacies. Lilly said patients must refill their prescriptions of the two higher dose vials within 45 days of their first fill to get the same pricing, and would otherwise have to pay as much as $699 for repeat prescriptions. Jonsson said this requirement ensures patients comply with a dosing regimen approved by the FDA. Sign in to access your portfolio
Al Arabiya
25-02-2025
- Business
- Al Arabiya
Lilly launches higher dose of weight loss drug for $150 less than injector pen
Eli Lilly said on Tuesday it has begun selling higher doses of its popular weight-loss drug Zepbound in vials in the US at a $150 discount to the cost of the injector pen versions, as it seeks to spur further demand for the medicine. The drugmaker said patients could purchase 7.5 milligram and 10mg vials of Zepbound for $499 a month on the LillyDirect website. That is nearly 23 percent less than the $650 Lilly charges for auto-injectors of the drug to patients who are insured but not covered for the medicine. The US drugmaker last August launched vials of the two lowest doses of Zepbound, which is typically sold in auto-injector pens, to help increase availability. On Tuesday, it said it had also cut the prices for a month's supply of those doses by around $50 each. They now cost $349 and $499 a month through LillyDirect. Patrik Jonsson, Eli Lilly's president of cardiometabolic health, said in an interview that more than 10 percent of patients starting on Zepbound have been initiated on vials since their launch. Lilly is looking for ways to stimulate further demand for Zepbound this year to help ease investor agitation over signs of weakness in sales, and to better compete with Danish rival Novo Nordisk's popular Wegovy. Novo offers Wegovy on its website for $650 for a month's supply to patients not covered by insurance for the drug, but does not sell its medicine in vials. Lilly's new offer of $499 per month is still higher than the $231 to $330 compounding pharmacies typically charge for their versions of Zepbound and Wegovy in the US, although compounders have been told to cease selling their copies in the coming months. Shortages of the weight-loss drugs pushed patients to cheaper compounded versions, which can be sold and distributed in bulk as long as the original drug is on the US Food and Drug Administration's shortage list. In the past three months, the FDA took both Zepbound and Wegovy off its shortage list, spurring lawsuits from compounding pharmacies. Lilly said patients must refill their prescriptions of the two higher dose vials within 45 days of their first fill to get the same pricing, and would otherwise have to pay as much as $699 for repeat prescriptions. Jonsson said this requirement ensures patients comply with a dosing regimen approved by the FDA.
